Sign up to save your podcasts
Or
Share BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.
View all episodes
By BiotechTV
4.3
66 ratings
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.
More shows like BiotechTV - News
View all
Motley Fool Money
3,222 Listeners
Odd Lots
1,910 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
324 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,957 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Business Breakdowns
353 Listeners
Biotech Hangout
19 Listeners
Bloomberg Tech
60 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
512 Listeners
Uncapped with Jack Altman
41 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners
Cheeky Pint
48 Listeners